DataSheet1_Neuropsychiatric disorders in chronic hepatitis C patients after receiving interferon or direct-acting antivirals: a nationwide cohort study.docx

Background: Data on the neuropsychological outcomes after receiving direct-acting antivirals (DAAs) among chronic hepatitis C (CHC) patients have not been well-documented.Aim: This study aimed to evaluate the difference in incidence of neuropsychological disorders (NPDs) after treatment completion between CHC patients receiving interferon (IFN) therapy and DAA therapy.Methods: A nationwide retrospective cohort study was performed using Taiwan’s National Health Insurance Research Database (NHIRD) between 2010 and 2018. CHC patients without pre-existing mental disorders were included and divided into the treatment (Tx)-naïve DAA group, retreatment (re-Tx) DAA group, and Tx-naïve IFN group based on their HCV therapy. Propensity score matching was used to balance baseline differences between groups. The primary outcome was the incidence of NPDs during 6 months after completion of therapy.Results: After one-to-one matching, there were 6,461 pairs of patients selected from the Tx-naïve DAA group and Tx-naïve IFN group and 3,792 pairs from the re-Tx DAA group and Tx-naïve IFN group. A lower incidence of NPDs was observed in the Tx-naïve DAA group than in the Tx-naïve IFN group (HR = 0.72, 95% CI = 0.55–0.94, and p = 0.017). The risk of NPDs did not differ between the re-Tx DAA group and the Tx-naïve IFN group (HR = 0.74, 95% CI: 0.52–1.05, and p = 0.092).Conclusion: DAA therapy was associated with lower risk of NPDs when compared with IFN therapy among Tx-naïve CHC patients in a 6-month period after treatment completion, especially among the patients less than 65 years, male gender, and cirrhosis.</p

Additional file 2: of Long noncoding RNA TUG1 is downregulated in non-small cell lung cancer and can regulate CELF1 on binding to PRC2

RIP and DNA ChIP. (DOCX 15 kb

Additional file 5: Figure S1. of Long noncoding RNA TUG1 is downregulated in non-small cell lung cancer and can regulate CELF1 on binding to PRC2

Digestion and PCR amplification of the TUG1-4C procedure. (A) Agarose gel (0.8 %, wt/vol) of the undigested (left lane) and primary digested (right lane) sample (HindIII, six-cutter). (B) Agarose gel (2.0 %, wt/vol) of the secondary digested sample (CViQI, four-cutter). (C) Inverse PCR amplification of the 4C samples generated amplified sequences of a wide range of sizes. (JPG 26 kb

Factors associated with spontaneous HCV seroclearance in 59 anti-HCV (+) patients.

<p>Factors associated with spontaneous HCV seroclearance in 59 anti-HCV (+) patients.</p

Differences of characteristics between subjects with or without HBsAg seropositivity.

<p>Differences of characteristics between subjects with or without HBsAg seropositivity.</p

Seroprevalence of anti-HCV and HBsAg seropositivity in thalassemic and hemophilic patients with different age groups.

<p>Seroprevalence of anti-HCV and HBsAg seropositivity in thalassemic and hemophilic patients with different age groups.</p

Univariate and multivariate analysis of factors associated with anti-HCV seropositivity.

<p>Univariate and multivariate analysis of factors associated with anti-HCV seropositivity.</p